Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 7
2016 11
2017 12
2018 19
2019 30
2020 35
2021 32
Text availability
Article attribute
Article type
Publication date

PubMed (MeSH Keyword) for id: 71731823

132 results
Results by year
Filters applied: . Clear all
Page 1
Lorlatinib in a Child with ALK-Fusion-Positive High-Grade Glioma.
Bagchi A, Orr BA, Campagne O, Dhanda S, Nair S, Tran Q, Christensen AM, Gajjar A, Furtado LV, Vasilyeva A, Boop F, Stewart C, Robinson GW. Bagchi A, et al. N Engl J Med. 2021 Aug 19;385(8):761-763. doi: 10.1056/NEJMc2101264. N Engl J Med. 2021. PMID: 34407349 No abstract available.
Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT, Chiang CL, Hung JY, Lee MH, Su WC, Wu SY, Wei YF, Lee KY, Tseng YH, Su J, Chung HP, Lin CB, Ku WH, Chiang TS, Chiu CH, Shih JY. Lin YT, et al. Eur J Cancer. 2021 Oct;156:1-11. doi: 10.1016/j.ejca.2021.06.043. Epub 2021 Aug 13. Eur J Cancer. 2021. PMID: 34392186 Free article.
Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade.
Nielsen SR, Strøbech JE, Horton ER, Jackstadt R, Laitala A, Bravo MC, Maltese G, Jensen ARD, Reuten R, Rafaeva M, Karim SA, Hwang CI, Arnes L, Tuveson DA, Sansom OJ, Morton JP, Erler JT. Nielsen SR, et al. Nat Commun. 2021 Jun 7;12(1):3414. doi: 10.1038/s41467-021-23731-7. Nat Commun. 2021. PMID: 34099731 Free PMC article.
132 results